Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

Expert commentary on melanoma immunotherapy latest

Dr Jeffrey Weber, Dr Axel Hauschild, Dr Dummer Reinhard
Expert commentary on melanoma immunotherapy latest ( Dr Jeffrey Weber, Dr Axel Hauschild, Dr Dummer Reinhard )
11 Sep 2017

Vemurafenib for high risk melanoma patients

Dr Karl Lewis - University of Colorado Denver, Colorado, USA
Vemurafenib for high risk melanoma patients ( Dr Karl Lewis - University of Colorado Denver, Colorado, USA )
11 Sep 2017

Dabrafenib plus trametinib for stage III mutant melanoma

Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
Dabrafenib plus trametinib for stage III mutant melanoma ( Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )
11 Sep 2017

Nivolumab vs ipilimumab for high risk melanoma patients

Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA
Nivolumab vs ipilimumab for high risk melanoma patients ( Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA )
11 Sep 2017

New strategies in melanoma care

Dr Alexander van Akkooi - Netherlands Cancer Institute, Amsterdam, Netherlands
New strategies in melanoma care ( Dr Alexander van Akkooi - Netherlands Cancer Institute, Amsterdam, Netherlands )
10 Sep 2017

Real-world productivity of advanced gastric cancer patients

Dr Marta Contente - Bristol-Myers Squibb, Uxbridge, UK
Real-world productivity of advanced gastric cancer patients ( Dr Marta Contente - Bristol-Myers Squibb, Uxbridge, UK )
10 Sep 2017

Abemaciclib for advanced breast cancer

Dr Angelo Di Leo - Hospital of Prato, Tuscany, Italy
Abemaciclib for advanced breast cancer ( Dr Angelo Di Leo - Hospital of Prato, Tuscany, Italy )
10 Sep 2017

Comment: MONARCH 3 trial: Abemaciclib for advanced breast cancer

Dr Evandro de Azambuja - Jules Bordet Institute, Brussels, Belgium
Comment: MONARCH 3 trial: Abemaciclib for advanced breast cancer ( Dr Evandro de Azambuja - Jules Bordet Institute, Brussels, Belgium )
10 Sep 2017

CheckMate 214: nivolumab ipilimumab vs sunitinib for advanced or metastatic renal cell carcinoma

Dr Bernard Escudier - Institut Gustave Roussy, Villejuif, France
CheckMate 214: nivolumab ipilimumab vs sunitinib for advanced or metastatic renal cell carcinoma ( Dr Bernard Escudier - Institut Gustave Roussy, Villejuif, France )
10 Sep 2017

RANGE: docetaxel with or without ramucirumab for metastatic urothelial carcinoma

Prof Daniel Petrylak - Yale Cancer Center, New Haven, Connecticut, USA
RANGE: docetaxel with or without ramucirumab for metastatic urothelial carcinoma ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, Connecticut, USA )
10 Sep 2017

Chemotherapy then surgery no better than concomitant chemoradiation for advanced cervical cancer

Prof Sudeep Gupta - Tata Memorial Hospital, Mumbai, India
Chemotherapy then surgery no better than concomitant chemoradiation for advanced cervical cancer ( Prof Sudeep Gupta - Tata Memorial Hospital, Mumbai, India )
10 Sep 2017

MONARCH 3: Abemaciclib as initial therapy for patients with HR /HER2- advanced breast cancer

Dr Angelo Di Leo - Hospital of Prato, Tuscany, Italy
MONARCH 3: Abemaciclib as initial therapy for patients with HR /HER2- advanced breast cancer ( Dr Angelo Di Leo - Hospital of Prato, Tuscany, Italy )
10 Sep 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation